Induced pluripotent stem cell derived neutrophil based leukocyte infusion therapy - LIfT Biosciences
Alternative Names: IMAN (iPSC) - LIfT BioSciencesLatest Information Update: 21 Jul 2024
At a glance
- Originator LIfT Biosciences
- Class Antineoplastics; Immunotherapies; Induced pluripotent stem cell therapies
- Mechanism of Action Immunologic cytotoxicity; Leukocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 May 2024 Pharmacodynamics data from preclinical studies in Solid tumour presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 03 Jan 2024 Preclinical trials in Solid tumours (Combination therapy) in United Kingdom (Parenteral) prior to January 2024 (LIfT Biosciences pipeline, January 2024)
- 03 Aug 2023 Induced pluripotent stem cell derived neutrophil based leukocyte infusion therapy is available for licensing as of 03 Aug 2023. https://www.liftbiosciences.com/